1887

Abstract

Recently, we and others have shown that the interaction between envelope specific antibodies and primary human immunodeficiency virus type 1 (HIV-1) isolates may result in either inhibition or enhancement of virus entry. The outcome proved to be determined by the virus isolate rather than by the specificity of the antiserum used. To study the mechanism underlying this phenomenon, a series of HIV-1 envelope glycoproteins from closely related primary virus isolates of different syncytium inducing phenotypes, together with chimeras of these proteins, were tested in an envelope transcomplementation assay for their sensitivity to either antibody mediated inhibition or enhancement of HIV-1 entry. Based on the observation that, in contrast to the inhibition of HIV-1 entry, antibody mediated enhancement was not temperature dependent and could not be mediated by F(ab) fragments, we concluded that the mechanisms underlying these phenomena are different and that antibody mediated enhancement of HIV-1 entry is largely if not exclusively mediated by HIV-1 glycoprotein cross-linking. The susceptibility of the envelope glycoprotein chimeric viruses to neutralization or enhancement of infectivity proved to be primarily determined by the configuration of the V3 loop, and the affinity of the antibodies to monomeric HIV-1 gp160 molecules, proved to be of quantitative importance only. One human monoclonal antibody directed against gp41 (IAM 2F5) inhibited entry of all the viruses studied, irrespective of their phenotype, and directly proportional to its affinity to monomeric HIV-1 gp160.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-5-999
1997-05-01
2022-08-11
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/5/9152416.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-5-999&mimeType=html&fmt=ahah

References

  1. Allan J. S. 1991; Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science 252:1322–1323
    [Google Scholar]
  2. Andeweg A. C., Groenink M., Leeflang P., de Goede R. E. Y., Osterhaus A. D. M. E., Tersmette M., Bosch M. L. 1992; Genetic and functional analysis of a set of HIV-1 envelope genes obtained from biological clones with varying syncytium-inducing capacities. AIDS Research and Human Retroviruses 8:1803–1813
    [Google Scholar]
  3. Andeweg A. C., Leeflang P., Osterhaus A. D. M. E., Bosch M. L. 1993; Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. Journal of Virology 67:3232–3239
    [Google Scholar]
  4. Burton D. R., Pyati J., Koduri R., Sharp S. J., Thornton G. B., Parren P. W., Sawyer L. S., Hendry R. M., Dunlop N., Nara P. L., Lamacchia M., Garratty E., Stiehm E. R., Bryson Y. J., Moore J. P., Ho D. D., Barbas C. F.III 1994; Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024–1027
    [Google Scholar]
  5. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D., Wu L., Mackay C. R., LaRosa G., Newman W., Gerard N., Gerard C., Sodroski J. 1996; The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135–1148
    [Google Scholar]
  6. Clapham P. R., Weber J. N., Whitby D., Mcintosh K., Dalgleish A. G., Maddon P. J., Deen K. C., Sweet R. W., Weiss R. A. 1989; Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 337:368–370
    [Google Scholar]
  7. Clapham P. R., McKnight A., Weiss R. A. 1992; Human immuno-deficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. Journal of Virology 66:3531–3537
    [Google Scholar]
  8. de Jong J. J., Goudsmit J., Keulen W., Klaver B., Krone W., Tersmette M., de Ronde A. 1992; Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. Journal of Virology 66:757–765
    [Google Scholar]
  9. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzi P., Marmon S., Sutton R. E., Hill C. M., Davis C. B., Peiper S. C., Schall T. J., Littman D. R., Landau N. R. 1996; Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661–666
    [Google Scholar]
  10. Doranz B. J., Rucker J., Yi Y., Smyth R. J., Samson M., Peiper S. C., Parmentier M., Collman R. G., Doms R. W. 1996; A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149–1158
    [Google Scholar]
  11. Eaton A. M., Ugen K. E., Weiner D. B., Wildes T., Levy J. A. 1994; An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Research and Human Retroviruses 10:13–18
    [Google Scholar]
  12. Feng Y., Broder C. C., Kennedy P. E., Berger E. A. 1996; HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 2 72:872–877
    [Google Scholar]
  13. Gluzman Y. 1981; SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23:175–182
    [Google Scholar]
  14. Gorny M. K., Xu J. Y., Karwowska S., Buchbinder A., Zolla-Pazner S. 1993; Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. Journal of Immunology 150:635–643
    [Google Scholar]
  15. Groenink M., Andeweg A. C., Fouchier R. A. M., Broersen S., van der Jagt R. C., Schuitemaker H., de Goede R. E. Y., Bosch M. L., Huisman H. G., Tersmette M. 1992; Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones : evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. Journal of Virology 66:6175–6180
    [Google Scholar]
  16. Helseth E., Kowalski M., Gabuzda D., Olshevsky U., Haseltine W., Sodroski J. 1990; Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. Journal of Virology 64:2416–2420
    [Google Scholar]
  17. Innocenti-Francillard P., Brengel K., Guillon C., Mallet F., Morand P., Gruters R., Seigneurin J. M. 1994; Blood monocytes infected in vivo by HIV-1 variants with a syncytium-inducing phenotype. AIDS Research and Human Retroviruses 10:683–690
    [Google Scholar]
  18. Kostrikis L. G., Cao Y., Ngai H., Moore J. P., Ho D. D. 1996; Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I : lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. Journal of Virology 70:445–458
    [Google Scholar]
  19. Maddon P. J., Dalgleish A. G., McDougal J. S., Clapham P. R., Weiss R. A., Axel R. 1986; The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333–348
    [Google Scholar]
  20. Malvoisin E., Wild F. 1994; Analysis of the human immunodeficiency virus type 1 envelope protein interaction with the CD4 host cell receptor. Journal of General Virology 75:839–847
    [Google Scholar]
  21. Moore J. P. 1990; Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. AIDS 4:297–305
    [Google Scholar]
  22. Moore J. P., McKeating J. A., Weiss R. A., Sattentau Q. J. 1990; Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250:1139–1142
    [Google Scholar]
  23. Moore J. P., McKeating J. A., Weiss R. A., Clapham P. R., Sattentau Q. J. 1991; Receptor mediated activation of immunodeficiency viruses in viral fusion. Science 252:1322–1323
    [Google Scholar]
  24. Moore J. P., McKeating J. A., Huang Y. X., Ashkenazi A., Ho D. D. 1992; Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. Journal of Virology 66:235–243
    [Google Scholar]
  25. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F.III Burton D. R., Ho D. D. 1995; Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. Journal of Virology 69:101–109
    [Google Scholar]
  26. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. 1993; A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Journal of Virology 67:6642–6647
    [Google Scholar]
  27. Orloff S. L., Kennedy M. S., Belperron A. A., Maddon P. J., McDougal J. S. 1993; Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. Journal of Virology 67:1461–1471
    [Google Scholar]
  28. Poignard P., Fouts T., Naniche D., Moore J. P., Sattentau Q. J. 1996; Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. Journal of Experimental Medicine 183:473–484
    [Google Scholar]
  29. Roben P., Moore J. P., Thali M., Sodroski J., Barbas C. F.III Burton D. R. 1994; Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Journal of Virology 68:4821–4828
    [Google Scholar]
  30. Robinson W. E.Jr Montefiori D. C., Mitchell W. M. 1990; Complement-mediated antibody-dependent enhancement of HIV-1 in-fection requires CD4 and complement receptors. Virology 175:600–604
    [Google Scholar]
  31. Sattentau Q. J., Moore J. P. 1991; Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. Journal of Experimental Medicine 174:407–415
    [Google Scholar]
  32. Sattentau Q. J., Moore J. P., Andeweg A. C., Schutten M., Osterhaus A. D. M. E., Schuitemaker H. 1994; gp120 interactions. In Neuvième Colloque Des Cent Gardes pp. 135–139 Marnes-La Coquette/Paris, France:
    [Google Scholar]
  33. Schuitemaker H., Koot M., Kootstra N. A., Dercksen M. W., de Goede R. E. Y., van Steenwijk R. P., Lange J. M., Schattenkerk J. K., Miedema F., Tersmette F. 1992; Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. Journal of Virology 66:1354–1360
    [Google Scholar]
  34. Schutten M., McKnight A., Huisman R. C., Thali M., McKeating J. A., Sodroski J., Goudsmit J., Osterhaus A. D. M. E. 1993; Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. AIDS 7:919–923
    [Google Scholar]
  35. Schutten M., Andeweg A. C., Bosch M. L., Osterhaus A. D. M. E. 1995a; Enhancement of infectivity of a non-syncytium inducing HIV- 1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scandinavian Journal of Immunology 41:18–22
    [Google Scholar]
  36. Schutten M., Langedijk J. P. M., Andeweg A. C., Huisman R. C., Meloen R. H., Osterhaus A. D. M. E. 1995b; Characterization of a V3 domain-specific neutralizing human monoclonal antibody that preferentially recognizes non-syncytium-inducing human immuno-deficiency virus type 1 strains. Journal of General Virology 76:1665–1673
    [Google Scholar]
  37. Schutten M., Tenner-Racz K., Racz P., Van Bekkum D. W., Osterhaus A. D. M. E. 1996; Human antibodies that neutralize primary human immunodeficiency virus type 1 in vitro do not provide protection in an in vivo model. Journal of General Virology 77:1667–1675
    [Google Scholar]
  38. Seed B., Sheen J. 1988; A simple phase extraction assay for chloramphenicol acetyltransferase activity. Gene 67:271–277
    [Google Scholar]
  39. Smith S. D., Shatsky M., Cohen P. S., Warnke R., Link M. P., Glader B. E. 1984; Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Research 44:5657–5660
    [Google Scholar]
  40. Stein B. S., Gowda S. D., Lifson J. D., Penhallow R. C., Bensch K. G., Engleman E. G. 1987; pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 49:659–668
    [Google Scholar]
  41. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J. 1995; Replicative function and neutralization sensitivity of envelope glyco-proteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. Journal of Virology 69:4413–4422
    [Google Scholar]
  42. Teeuwsen V. J. P., Siebelink C. H. J., Crush-Stanton S., Swerdlow B., Schalken J. J., Goudsmit J., van de Akker R., Stukart M. J., Uytdehaag F. G. C. M., Osterhaus A. D. M. E. 1990; Production and characterization of a human monoclonal antibody, reactive with a conserved epitope on gp41 of human immunodeficiency virus type I. AIDS Research and Human Retroviruses 6:381–392
    [Google Scholar]
  43. Werner A., Winskowsky G., Kurth R. 1990; Soluble CD4 enhances simian immunodeficiency virus SIVagm infection. Journal of Virology 64:6252–6256
    [Google Scholar]
  44. Wu L., Gerard N. P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A. A., Desjardin E., Newman W., Gerard G., Sodroski J. 1996; CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179–183
    [Google Scholar]
  45. Zolla-Pazner S., O’Leary J., Burda S., Gorny M. K., Kim M., Mascola J., McCutchan F. 1995; Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. Journal of Virology 69:3807–3815
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-5-999
Loading
/content/journal/jgv/10.1099/0022-1317-78-5-999
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error